Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...

Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting ...

Insights from ASH 2025, including anticipated presentations, key takeaways, and how emerging research in paroxysmal nocturnal ...

When a parent’s health declines, doctors must navigate difficult, overlapping roles, balancing clinical knowledge with ...

Edward S. Cooper, MD, the American Heart Association’s first Black president, leaves behind an indelible mark on stroke ...

Christmas traditions such as decorating a tree and singing not only lift spirits but also boost immunity by triggering immune ...

Growth hormone replacement therapy improves physical fitness, lifestyle habits, and quality of life in children with growth ...

Dr Kami Maddocks reflects on fresh data, such as the new epcoritamab combo approval, evolving CD19 sequencing data, and ...

Semaglutide use is linked to fewer hospitalizations and fewer days in the hospital for patients with cardiovascular disease ...

Menopause hormone therapy neither increases nor decreases the risk for dementia or mild cognitive impairment in ...

The progress in understanding the pathophysiology of hidradenitis suppurativa appears to be leading to treatment strategies ...